EcoDrugPlus

Sodium/potassium-Transporting Atpase Subunit Beta-233-Like

Ensembl ID : ENSSLDG00000015154
Gene Symbol: LOC111670259
3 Cross references
220 Possible Orthologues:

Sodium/potassium-Transporting Atpase Subunit Beta-3-Like

Ensembl ID : ENSSLDG00000005601
Gene Symbol: LOC111646682
3 Cross references
232 Possible Orthologues:

Solute Carrier Family 10 Member 2

Ensembl ID : ENSSLDG00000012435
Gene Symbol: SLC10A2
3 Cross references
214 Possible Orthologues:

Solute Carrier Family 18 Member A2

Ensembl ID : ENSSLDG00000018015
Gene Symbol: SLC18A2
3 Cross references
216 Possible Orthologues:

Solute Carrier Family 22 Member 6

Ensembl ID : ENSSLDG00000018286
Gene Symbol: LOC111666301
3 Cross references
358 Possible Orthologues:

Solute Carrier Family 29 Member 1 (Augustine Blood Group)

Ensembl ID : ENSSLDG00000022484
Gene Symbol: SLC29A1
3 Cross references
209 Possible Orthologues:

Solute Carrier Family 29 Member 1 (Augustine Blood Group)

Ensembl ID : ENSSLDG00000003346
Gene Symbol: SLC29A1
3 Cross references
210 Possible Orthologues:

Solute Carrier Family 5 Member 1

Ensembl ID : ENSSLDG00000015946
Gene Symbol: SLC5A1
3 Cross references
250 Possible Orthologues:

Solute Carrier Family 5 Member 2

Ensembl ID : ENSSLDG00000000683
Gene Symbol: SLC5A2
3 Cross references
198 Possible Orthologues:

Solute Carrier Family 6 Member 1

Ensembl ID : ENSSLDG00000004413
Gene Symbol: SLC6A1
3 Cross references
209 Possible Orthologues:

Solute Carrier Family 6 Member 2

Ensembl ID : ENSSLDG00000015724
Gene Symbol: SLC6A2
3 Cross references
203 Possible Orthologues:

Solute Carrier Family 6 Member 3

Ensembl ID : ENSSLDG00000020009
Gene Symbol: SLC6A3
3 Cross references
166 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).